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MTHFR 677 C-TAbstract Background: Different genetic and non-genetic factors have been reported to play a role
in human longevity. Longevity has been associated with genetically favourable conditions which
protected humans from cardiovascular disease (CVD). We have tried to conﬁrm this statement
in Turkish young and old aged groups.
Aim of the study: We aimed to investigate selected genetic polymorphisms (Factor V 1691 G-A,
Prothrombin 20210 G-A and methylenetetrahydrofolate reductase 677 C-T) in CVD and controls
to analyse their effects on longevity.
Patients and methods: The case control study included 362 persons aged 0–18 years and 209 per-
sons aged 70 and above with diagnosis of thrombosis. Genetic polymorphisms were detected with
Light Cycler Real Time PCR.
Results: The results were compared to those of 332 and 266 healthy persons of same age groups
who served as controls. MTHFR 677 C-T and PT 20210 G-A genotype frequencies in the old and
young study groups were similar for all polymorphisms, but MTHFR 677T may have synergy with
FVL (Factor V Leiden) imparting a risk of thromboembolism.
Conclusion: This study concludes that common variations in genes associated with cardiovascu-
lar risk do not contribute signiﬁcantly to longevity.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.
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The search for factors involved in aging and longevity has pro-
gressed extensively in recent years because of increased human
life expectancy and elevation of the number of elderly people
which in turn results in increased prevalence of age-related
illnesses [1]. There is large variation in the maximum age which
human reach before they die. The age of demise is determined
by environmental factors as well as genetic factors [2–10].
In today’s world a major cause of mortality is cardiovascu-
lar disease which is a multifactorial disease such as stroke,
thrombosis, and acute myocardial infarction. Several varia-
tions in genes involved in haemostasis and blood pressure reg-
ulation have been associated with the evolution of CVD, either
directly or through their association with blood levels of CVD
risk factors [2-4-5-6-7-11]. Venous thromboembolism is the
most prevalent signiﬁcant CVD after ischaemic heart disease
and stroke, and 1 in 1000 individuals is affected annually [11].
The aetiology of thromboembolism is thought to be multi-
factorial and caused by congenital and acquired risk factors.
Among inherited factors are FV 1691 G-A, PT 20210 G-A,
and MTHFR 677 C-T single nucleotide polymorphisms.
FVL is the leading cause of constitutional thrombophilia
[11]. This gene defects include G-A transition at nucleotide
1691 in exon 10 of the FV gene causing APC (Activated Pro-
tein C) resistance [12]. The PT 20210 G-A polymorphism is the
second most common inherited risk factor for thrombophilia.
The polymorphism is located at position 20210 in the 30
untranslated region of the prothrombin gene and is caused
by single base change G-A. Carriers of the rare A allele have
higher prothrombin levels than carriers of the G allele and a
higher risk of venous thrombosis and myocardial infarction.
The hyperhomocysteinemia is also a risk factor for cerebrovas-
cular, peripheral vascular, coronary heart disease and throm-
boembolism. The polymorphism is located in nucleotide 677
in the MTHFR gene and is caused by single base change C-
T leading to an amino acid replacement of alanine (A) to
valine (V) at MTHFR enzyme. Carriers of the 677T allele have
thermolabile MTHFR enzyme and higher plasma homocyste-
ine concentration than carriers of the 677A allele and have
been associated with an increased cardiovascular risk [1-3-4-6].Table 1 Genotype distributions and frequencies in elderly and you
Polymorphisms 0–18
Age controls
n= 332 (%)
70 and above
controls n= 26
FV 1691 G-A
G/G 294 (88.5) 237 (89)
G/A 35 (10.5) 29 (11)
A/A 3 (0.9) _
PT 20210 G-A
G/G 314 (94.5) 254 (95)
G/A 18 (5) 11 (4)
A/A _ 1 (0.3)
MTHFR677 C/T
C/C 174 (52) 138 (52)
C/T 126 (38) 108 (41)
T/T 32 (10) 20 (7.5)Comparison of genotype frequencies in very old people and
in young people may be a useful tool to study the effect of
genetic polymorphisms on CVD causing premature death [2].
The aim of this study was to evaluate the effect of some
cardiovascular, thrombotic risk factors on longevity such as
Factor V (FV) 1691 G-A, Prothrombin (PT) 20210 G-A and
methylenetetrahydrofolate reductase (MTHFR) 677 C-T to
determine the role of combination of mutations in Turkish
young and old groups. We have studied selected genetic poly-
morphisms in CVD and controls to analyse the effect of these
Single nucleotide polymorphisms (SNPs) on longevity.2. Patients and methods
2.1. Study populations
Our case control study included patients with clinical throm-
bosis aged between 0 and 18 (362 individuals), and 70 years
and over (209) as well as 332 individuals aged 0–18 years
and 266 individuals aged 70 years and above and healthy
individuals as control group. An informed written consent
was obtained from all the patients’ parents. The study is car-
ried out in accordance with the code of Ethics of the World
Medical Association (Declaration of Helsinki) for experiments
involving humans.
2.2. DNA Isolation and FV 1691 G-A, PT 20210 G-A, MTHFR
677C-T Mutations Light Cycler Real Time PCR Screening
Blood samples were collected with Ethylenediaminetetraacetic
acid (EDTA) containing tubes and deoxyribose nucleic acid
(DNA) was extracted from peripheral blood leukocytes
according to MagNA Pure DNA isolation system (Roche
Diagnostics, Manheim, Germany). Genotyping of FV 1691
G-A, PT 20210 G-A, and MTHFR 677C-T polymorphisms
was performed by real time PCR (polymerase chain
reaction) using ﬂuorescence melting curve detection
analysis by means of the Light Cycler (LC) System (Roche
Diagnostics, Manheim, Germany). For FV; forward
primer: 50-TGCCCAG TGCTTAACAAGACCA-30; reverseng subjects.
6 (%)
0–18
Age patients
n= 362 (%)
70 and above
patients n= 209 (%)
304 (84) 173 (83)
53 (15) 33 (16)
5 (1) 3 (1)
348 (96) 197 (94)
14 (4) 12 (6)
_ _
173 (48) 91 (43,5)
157 (43) 106 (51)
32 (9) 12 (6)
Table 2 Combined risk assessment of two gene polymorphisms (FV 1691 G-A and MTHFR 677 C-T) between 70 and above age
groups in patients and controls.
FV 1691 G-A MTHFR 677 C-T 70 and above
controls n= 266 (%)
70 and above
patients n= 209 (%)
OR CI (%95) P
G/G C/C 137 (51.5) 88 (42) 1
G/G C/T 92 (34.5) 73 (35) 1.2 0.8–1.8 0.3
G/G T/T 18 (6.8) 10 (4.8) 0.8 0.3–1.9 0.7
G/A C/C 11 (4) 14 (6.7) 1.9 0.8–4.5 0.09
G/A C/T 15 (5.6) 18 (8.6) 1.8 0.8–3.8 0.08
G/A T/T 2 (0.7) 1 (0.4) 0.7 0.06–8.7 0.6
A/A C/C – 2 (0.95) 6.2 0.2–139 0.01
A/A C/T – 1 (0.4) 3.1 0.1–93.7 0.5
A/A T/T – – – – –
Table 3 Combined risk assessment of two gene polymorphisms (FV 1691 G-A and MTHFR 677 C-T) between 0 and 18 age, groups
in patients and controls.
FV 1691 G-A MTHFR 677 C-T 0–18 Age
controls n= 332 (%)
0–18 Age
patients n= 362 (%)
OR CI (%95) P
G/G C/C 148 (44.5) 143 (39.5) 1
G/G C/T 113 (34) 132 (36) 1.2 0.8–1.6 0.2
G/G T/T 28 (8) 21 (5.8) 0.7 0.4–1.4 0.5
G/A C/C 21 (6) 25 (7) 1.2 0,6–2.2 0.5
G/A C/T 11 (3) 20 (5.5) 1.8 0.8–4.0 0.09
G/A T/T 3 (0.9) 5 (1.3) 1.7 0.4–7,3 0.7
A/A C/C 2 (0.6) 4 (1.1) 2.0 0.3–11,4 0.6
A/A C/T – 1 (0.2) 2.0 0.06–62 0.2
A/A T/T 1 (0.3) – 0.5 0.01–15 0.2
Table 4 Combined risk assessment of two gene polymorphisms (FV 1691 G-A and PT 20210 G-A) between 70 and above age groups
in patients and controls.
FV 1691 G-A PT 20210 G-A 70 and above
controls n= 266 (%)
70 and above
patients n= 209 (%)
OR CI (%95) P
G/G G/A 9 8 1
G/A G/A 2 2 1.1 0.12–9.9 0.6
G/A A/A 1 – 0.5 0.16–19.1 0.2
A/A G/A – 2 4.5 0.17–115 0.7
Common mutations in young and elderly groups 283primer: 50-CTTGAAGGAAATG CCCCATTA-30; anchor
hybridization probe: 50-LC-Red705-TGTCCTTGAAGTAA
CCTTTCAGAAATTCT G-30-PHO; Mutation probe: 50-GG
CGAGGAATACAGGTA T-30-ﬂoresan (Roche Diagnostics,
Mahheim, Germany) For Prothrombin; forward primer: 50-
CCGCTGGTATCAAATG GGG-30; reverse primer: 50-CCA
GTAGTATTACTGGCTCT TCCTG-30: anchor hybridiza-
tion probe: 50-LC-Red640-TCCCAGTGCTATTCATGGGC-
30PHO; Mutation probe: 50-CTC AGCGAGCCTCAATG-30
ﬂoresan (Roche Diagnostics, Manheim, Germany). For
MTHFR; forward primer: 50-TGG CAG GTT ACC CCA
AAG G-30; reverse primer: 50-TGA TGC CCA TGT CGG
TGC-30; anchor hybridization probe: 50-LC–640-CGG GAG
CCG ATT TCA TCA T-30-PHO; Mutation probe: 50-TGA
GGC TGA CCT GAA GCA CTT GAA GGA GAA GGT
GTC T-30-Flu.) were used (TIB MOLBION, Berlin, Ger-
many). Melting point analysis was performed according to
the instruction manual [13,14].3. Results
The genotype frequencies of the FV 1691 G-A, PT 20210 G-A
and MTHFR 677 C-T polymorphisms in old and young
subjects are shown in Table 1. There were no signiﬁcant differ-
ences in the allele frequency for PT 20210 G-A and MTHFR
677 C-T polymorphisms between the 0–18 age and 70 and
above groups. Possible effect of the FV 1691 G-A with other
polymorphisms (PT 20210 G-A, MTHFR 677 C-T) are given
in Tables 2–5. The frequencies of these mutation alleles in
the patient and control groups were similar.
Heterozygosities of FV 1691 G-A and MTHFR 677 C-T
substitutions’ state brought a risk of thrombosis in the patients
and controls aged 70 and above and 0 to 18 respectively [(Odd
Ratio (OR): 1.8/0.8–3.8 CI%95), (OR:1.8/0.8–4.0 CI%95)]
(Tables 2 and 3). Allelic distributions of FV 1691 G-A, PT
20210 G-A and MTHFR 677 C-T are given in Table 6
respectively.
Table 5 Combined risk assessment of two gene polymorphisms (FV 1691 G-A and PT 20210 G-A) between 0 and 18 age groups in
patients and controls.
FV 1691 G-A PT 20210 G-A 0 to 18 age controls n= 332 (%) 0 to 18 age patients n= 362 (%) OR CI (%95) P
G/G G/A 16 12 1
G/A G/A 1 1 1.3 0.07–23.5 0.5
Table 6 The allele frequencies of all study genes in all the groups.
Polymorphisms 0–18
Age controls
n= 332 (%)
70 and above
controls n= 266 (%)
0–18 Age
patients n= 362 (%)
70 and above
patients n= 209 (%)
FV 1691 G-A
G 93 95 91 91
A 0.06 0.05 0.08 0.09
PT 20210 G-A
G 97 97 98 97
A 0.02 0.02 0.01 0.02
MTHFR677 C/T
C 71 72 69 68
T 28 27 30 31
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Different genetic markers related with CVD and longevity,
have been investigated between young and elderly subjects in
various studies. In the present study, no signiﬁcant differences
were observed in genotype frequency between younger and
elderly subjects for polymorphisms in selected haemostasis
and cardiovascular risk indicators reported to be associated
with the CVD. In accordance with our results other studies
have reported a lack of relationship between single genetic
polymorphisms and longevity.
The hypothesis of MTHFR involvement in longevity is
based upon that the MTHFR TT genotype is associated with
higher levels of homocysteine and premature death; its preva-
lence should decrease with advancing age [15]. This has been
supported by a study of Masushita et al. who found a signiﬁ-
cant difference in frequency between younger and older
groups. The TT genotype frequency decreased from 19% to
7% in healthy Japanese individuals aged <55 versus
>80 years [16]. These ﬁndings were replicated by Todesco
et al. [17]. In a study, the MTHFR 677C-T polymorphism
was analysed in the elderly and young populations. Similar
proportions of all populations were reported for this
polymorphism [16].
The meta analysis by Brattsro¨m revealed no signiﬁcant dif-
ference in genotype between young and elderly [2]. Bladbjerg
et al. studied several genetic polymorphisms linked to vascular
risk, in addition to MTHFR 677C-T and PT 20210 G-A in 187
unselected Danish centenarians and 201 healthy Danish blood
donor (aged 20–64 years). The frequencies of the reported
high-vascular risk alleles of all these polymorphisms were com-
parable in centenarians to the blood donors, suggesting a lack
of association between these vascular risk factors and longev-
ity in Danish population [4–19]. On the other hand Sabino De
et al. reported that the present FV1691 G-A polymorphism
posed a signiﬁcant risk of thrombotic diseases, but PT20210G-A and MTHFR 677 C-T polymorphisms were not signiﬁ-
cant risk factors for the same disease in Brazil young popula-
tion [19]. The potential role in several investigators showed an
increased frequency of MTHFR 677 C-T mutation in patients
in a wide range of vascular diseases. In our study, comparison
of healthy populations, young patients and elderly populations
revealed no statistically signiﬁcant difference in the 677 C-T
genotype distribution. Our data suggested that MTHFR 677
C-T (3.1–2.0) and PT 20210 G-A (OR 4.5–1.3) may have little
effect on CVD and longevity.
The Turkish population is a model for researching the ef-
fects of genes since the establishment of the republic, there
had been neither a war causing the deaths nor a big natural
disaster, famine and also her economic development was sta-
ble. Thus, the comparison of genotype frequencies in young
and old individuals may be a useful method/tool to study the
effects of genetic polymorphisms on CVD causing premature
deaths.
We conclude that polymorphisms of haemostasis and blood
pressure regulation genes do not predict longevity because the
allele distributions were similar in Turkish elderly and younger
individuals. MTHFR 677 C-T and PT 20210 G-A genotype
frequencies in the old and young study groups were similar
for all polymorphisms, but MTHFR 677T may have synergy
with FVL imparting a risk of thromboembolism.
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